Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)
Public ClinicalTrials.gov record NCT01222702. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multi-center, Double-blind, Randomized, Active Reference, Parallel Group Study to Evaluate the Efficacy, Safety and Tolerability of a 10-day Twice Daily Oral Administration of Three Doses of Cadazolid (ACT-179811) in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)
Study identification
- NCT ID
- NCT01222702
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Actelion
- Industry
- Enrollment
- 84 participants
Conditions and interventions
Conditions
Interventions
- Cadazolid Drug
- Vancomycin Drug
- Placebo-matching cadazolid Drug
- Placebo-matching vancomycin Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 24, 2011
- Primary completion
- Oct 15, 2012
- Completion
- Nov 11, 2012
- Last update posted
- Jun 13, 2017
2011 – 2012
United States locations
- U.S. sites
- 11
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clinical Investigative Site 6902 | Newark | Delaware | 19718 | — |
| Clinical Investigative Site 6919 | Jacksonville | Florida | 32207 | — |
| Clinical Investigative Site 6938 | Orlando | Florida | 32837 | — |
| Clinical Investigative Site 6930 | Decatur | Georgia | 30033 | — |
| Clinical Investigative Site 6935 | Marietta | Georgia | 30060 | — |
| Clinical Investigative Site 6915 | Idaho Falls | Idaho | 83404 | — |
| Clinical Investigative Site 6906 | Chicago | Illinois | 60637 | — |
| Clinical Investigative Site 6917 | Boston | Massachusetts | 02111 | — |
| Clinical Investigative Site 6936 | Royal Oak | Michigan | 48073 | — |
| Clinical Investigative Site 6903 | Columbus | Ohio | 43215 | — |
| Clinical Investigative Site 6914 | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01222702, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 13, 2017 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01222702 live on ClinicalTrials.gov.